Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<div><ul><li style="list-style-type: square;">Clinical programs. Anixa has two key therapeutic programs: (1) a novel CAR-T cell therapy for terminally ill ovarian cancer patients; and (2) a breast cancer vaccine.</li><li style="list-style-type: square;">The CAR-T program targets resistant and recurrent ovarian cancer, while the breast cancer vaccine aims to treat current breast cancer, prevent recurrence in survivors, and ultimately offer primary prevention.</li><li style="list-style-type: square;">Strategic partnerships with institutions like Cleveland Clinic and Moffitt Cancer Center have helped keep trial costs in check, enabling Anixa to maintain an incredibly low annual cash burn rate of about $5-7MM.</li></ul></div>

Clinical programs. Anixa has two key therapeutic programs: (1) a novel CAR-T cell therapy for terminally ill ovarian cancer patients; and (2) a breast cancer vaccine.The CAR-T program targets resistant and recurrent ovarian cancer, while the breast cancer vaccine aims to treat current breast cancer, prevent recurrence in survivors, and ultimately offer primary prevention.Strategic partnerships with institutions like Cleveland Clinic and Moffitt Cancer Center have helped keep trial costs in check, enabling Anixa to maintain an incredibly low annual cash burn rate of about $5-7MM.

ANIX: Clinical Progress, Partnerships, and Financial Discipline

<ul><li>Anixa is a biotech company with two early-stage clinical developments: (1) a novel type of chimeric antigen receptor (CAR)-T-cell therapy for the treatment of terminally ill ovarian cancer patients; (2) and a breast cancer vaccine designed as both a treatment and prophylactic.</li><li>The vaccine is being used to train patients’ T-cells to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer.</li><li>Additionally, Anixa runs several pre-clinical programs.</li></ul>

Anixa is a biotech company with two early-stage clinical developments: (1) a novel type of chimeric antigen receptor (CAR)-T-cell therapy for the treatment of terminally ill ovarian cancer patients; (2) and a breast cancer vaccine designed as both a treatment and prophylactic.The vaccine is being used to train patients’ T-cells to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer.Additionally, Anixa runs several pre-clinical programs.

Anixa Biosciences' Innovative Approach to Help T- Cells Address Solid Tumors

Technology augmented investing

Lazarus Goh

Augmenting fundamental investing with technology

Open Diligence

We aim to a) increase the efficacy of investment processes with technology and b) utilize alternative data to gain an additional perspective on equity names

<p>Companies are most happy to announce new partnerships with potential customers or established firms that bolster credibility to their business and/or technology.</p><p>However, when such partnerships dissolve, some companies do not disclose the fact - they simply remove mentions of these partnerships in their disclosures. It is from these omissions that we discover potential dissolving of partnerships.</p><p>In the past weeks, two small-cap firms showed signs of such tendency.</p>

Companies are most happy to announce new partnerships with potential customers or established firms that bolster credibility to their business and/or technology.However, when such partnerships dissolve, some companies do not disclose the fact - they simply remove mentions of these partnerships in their disclosures. It is from these omissions that we discover potential dissolving of partnerships.In the past weeks, two small-cap firms showed signs of such tendency.

Dissolved Partnerships that Remain Undisclosed (January Screener)

United States

Anixa Biosciences, Inc. operates as a bio-technology company. The Company develops diagnostics and therapeutics to detect cancer. Anixa Biosciences serves clients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Anixa Biosciences Inc (ANIX US)

ANIX: Clinical Progress, Partnerships, and Financial Discipline

Clinical programs. Anixa has two key therapeutic programs: (1) a novel CAR-T cell therapy for terminally ill ovarian cancer patients; and (2) a...

Water Tower Research

Anixa Biosciences' Innovative Approach to Help T- Cells Address Solid Tumors

Anixa is a biotech company with two early-stage clinical developments: (1) a novel type of chimeric antigen receptor (CAR)-T-cell therapy for the...

Water Tower Research

Dissolved Partnerships that Remain Undisclosed (January Screener)

Two US-listed companies omitted the mention of key partners/customers in their recent annual report, suggesting that these partnerships have been...

Lazarus Goh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)